INO Stock Forecast: Inovio Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.76

The median 12-month analyst price target for Inovio Pharmaceuticals, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 49 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$320.3M
Ticker Nerd rank
49/ 100
Median analyst target
$6.00
Analysts covering
3
Revenue$0.0−100.0% y/y
Operating income−$21.9M
Net income−$19.7M
Free cash flow−$21.6M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Inovio Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
49/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Value
67
Accruals
63
Volatility
61
Issuance
47
Momentum
38
Revisions
34
Quality
16

Growth (85): Sales and profits are climbing, and climbing faster than before.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INO, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$5.00
Low
$6.00
Median
$8.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
12 Nov 2026HC Wainwright & Co.ReiteratesBuy$5.00
11 Nov 2026Piper SandlerReiteratesOverweight$8.00 → $6.00
7 Nov 2026JefferiesMaintainsBuy—
6 Nov 2026JefferiesMaintainsBuy$3.00 → $8.00
2 Nov 2026HC Wainwright & Co.UpgradeBuy$5.00
13 Aug 2026JefferiesUpgradeBuy$1.80 → $3.00
3 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $4.00
1 June 2026HC Wainwright & Co.MaintainsNeutral$3.00 → $2.50
14 Nov 2025Piper SandlerReiteratesOverweight—
14 Aug 2025HC Wainwright & Co.ReiteratesNeutral—
9 July 2025Piper SandlerInitiatesOverweight—
14 May 2025OppenheimerMaintainsOutperform—
14 May 2025RBC CapitalReiteratesSector Perform—
19 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
19 Mar 2025RBC CapitalMaintainsSector Perform—
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform$18
13 Jan 2025HC Wainwright & Co.MaintainsNeutral—
10 Jan 2025JMP SecuritiesReiteratesMarket Outperform—
18 Nov 2024HC Wainwright & Co.MaintainsNeutral—
18 Nov 2024OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INO.

Market Radar

This page is one stock. Monday covers all of them.

INO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

INO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1085.6×

Cheaper than 1% of US stocks

Price / book
23.3×

Cheaper than 3% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−352.5%

Higher than 4% of US stocks

Return on assets
−74.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inovio Pharmaceuticals, Inc. has a market value of $320.3M and an enterprise value of $279.2M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$84.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$83.6M, after $226K of capital spending.

  • Shares outstanding: 187.3M.

  • Inovio Pharmaceuticals, Inc. employs 112 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

INO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INOInovio Pharmaceuticals, Inc.$320.3M49
MPLTMapLight Therapeutics, Inc.$330.1M16
LRMRLarimar Therapeutics, Inc.$331.6M29
CCCCC4 Therapeutics, Inc.$325.7M65
CTNMContineum Therapeutics, Inc.$336.4M32
LYELLyell Immunopharma, Inc.$338.2M80
AVIRAtea Pharmaceuticals, Inc.$317.6M81

Take a look at INO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Inovio Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INO

What is the INO stock price forecast for 2026-2027?

The median 12-month analyst price target for Inovio Pharmaceuticals, Inc. is $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INO stock a buy right now?

Of the 3 analysts covering Inovio Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inovio Pharmaceuticals, Inc. 49 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INO?

As at 21 Nov 2026, Inovio Pharmaceuticals, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will INO stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $6, and Ticker Nerd's factor model ranks Inovio Pharmaceuticals, Inc. 49 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INO stock forecast for 2030?

No analyst covering Inovio Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications.

Company

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.

CEO Dr. Jacqueline E. Shea Ph.D. · 112 employees · United States · https://www.inovio.com